Cemiplimab plus OSE2101 as maintenance after chemo-immunotherapy for lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two drugs (cemiplimab and OSE2101) as ongoing treatment after initial chemo-immunotherapy for advanced lung cancer. It is for patients whose tumor DNA is still detectable in the blood, and who carry a specific immune marker called HLA-A2.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced non-small cell lung cancer (NSCLC) that cannot be removed by surgery.
- You are about to start or have recently started your first treatment with chemotherapy plus immunotherapy.
- You must have a specific genetic marker called HLA-A2 (a blood test can check this).
- Your general health is good enough to be up and about (ECOG score 0 or 1).
- You do not have certain gene changes (EGFR, ALK, ROS1) in your tumor.
- You have not had another cancer in the last 3 years, except for some skin cancers or early-stage cervical, breast, or bladder cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding two immunotherapy drugs (cemiplimab and fianlimab) to standard radiation and chemotherapy can help treat locally advanced non-small cell lung cancer that hasn't been treated before.
This trial tests a new way of giving chemotherapy and an immunotherapy drug (cemiplimab) before surgery for lung cancer that has a high PD-L1 level. The goal is to see if a shorter or adjusted course can shrink the tumor and improve outcomes while reducing side effects.
This study tests a new immunotherapy drug (cemiplimab) combined with chemotherapy for advanced squamous lung cancer. The treatment is chosen based on a blood test that measures a natural body enzyme, which may help predict how well the chemotherapy works.
This trial tests whether adding the immunotherapy drug cemiplimab to standard treatment can help people with advanced lung cancer that has already progressed after both platinum chemo and a prior immunotherapy. It is designed for those who responded to their first immunotherapy for at least 12 weeks before the cancer started growing again.
This trial tests a drug called cemiplimab (an immunotherapy) for people with advanced lung cancer that has high PD-L1 levels. It uses a simple blood test to track how well the treatment is working.
This trial is testing a combination of treatments (an immunotherapy drug called cemiplimab plus chemotherapy) for people with advanced lung cancer that has not been treated yet and shows a high PD-L1 level. The study also looks at a specific blood marker to see if it predicts how the cancer responds, aiming to avoid rapid growth (hyperprogression).
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.